![]() |
市場調查報告書
商品編碼
1486844
下腔靜脈過濾器 (IVCF) 的全球市場 - 市場分析、競爭格局、市場預測 (2030)Inferior Vena Cava Filters (IVCF) - Market Insights, Competitive Landscape and Market Forecast-2030 |
預計 2024 年至 2030 年預測期內,全球下腔靜脈過濾器 (IVCF) 市場規模將以 5.67% 的複合年增長率成長。下腔靜脈濾器(IVCF)的需求主要是由於肺栓塞和靜脈血栓栓塞盛行率的增加而推動的。此外,由於主要國家在產品開發、技術進步和設備批准方面的許多持續改進,促進了下腔靜脈市場的整體成長,預計該市場將會成長。這些是2024-2030年預測期內下腔靜脈市場積極成長的關鍵驅動因素。
下腔靜脈濾器(IVCF)市場動態
下腔靜脈濾器(IVCF)在預防肺栓塞和靜脈血栓栓塞方面發揮重要作用。根據澳洲政府衛生和老年護理部的研究 (2021),靜脈血栓栓塞 (VTE) 對健康構成重大威脅。肺栓塞每年影響超過 17,000 名澳洲人,隨著人口老化,肺栓塞的發生率也隨之增加。
此外,根據國家藥物圖書館(NIH)(2020)進行的 "急診室隊列中肺栓塞盛行率:依研究國家進行的系統性回顧和薈萃分析" 研究,肺栓塞盛行率為 23歐洲為%,北美為8%。因此,這些統計數據和數據預計將增加下腔靜脈過濾器 (IVCF) 的未來使用並推動未來市場。
此外,主要產業參與者不斷增加的器械批准也在推動下腔靜脈過濾器 (IVCF) 未來整體市場的發展中發揮著重要作用。 2022年12月,可回收式下腔靜脈過濾器(IVCF)ZYLOX Octoplus TM 獲得中國國家藥品監督管理局(NMPA)批准。此過濾器主要用於預防週邊血管深部靜脈血栓(DVT)引起的肺栓塞(PE)。隨著這些知名製造商的 IVCF 產品獲得監管部門的批准,醫療保健提供者渴望將這種先進的解決方案納入他們的治療方案中。他們的興趣在於改善患者的治療效果並最大限度地降低與靜脈血栓栓塞相關的風險。
此外,2024 年 1 月,Cook Medical 的 Celect Platinum 腔靜脈過濾器和 Gunther Tulip 腔靜脈過濾器獲得 FDA 批准。與先前的過濾器型號相比,Celect 腔靜脈過濾器的特點是靈活性更高且易於插入。此外,我們的復健率高達90%以上,為成功復健提供了進一步的保證。因此,最近對下腔靜脈過濾器(IVCF)的批准和需求的增加反映了下腔靜脈過濾器(IVCF)的未來市場成長。
但是,有以下問題的風險:下腔靜脈過濾器 (IVCF) 從其原始位置遷移、過濾器損壞、過濾器上出現孔、過濾器內形成血塊以及回收問題,可能會抑制下腔靜脈過濾器(IVCF)的市場需求。
下腔靜脈濾器(IVCF)市場細分分析
下腔靜脈過濾器 (IVCF) 市場產品細分,可回收下腔靜脈過濾器 (IVCF) 類別預計將在 2023 年佔據下腔靜脈過濾器 (IVCF) 市場的主要收入佔有率。這可能是由於可回收下腔靜脈過濾器 (IVCF) 提供的各種好處和應用。
本報告研究和分析了全球下腔靜脈過濾器 (IVCF) 市場,提供市場規模和預測、驅動因素和課題、公司和產品概況等。
Inferior Vena Cava Filters Market By Product Type (Retrievable Inferior Vena Cava Filters, Permanent Inferior Vena Cava Filters), Material (Non-Ferromagnetic Material, Ferromagnetic Materials), Application (Venous Thromboembolism, Pulmonary Embolism), End User (Hospitals, Ambulatory Surgical Centers, And Others), And Geography (North America, Europe, Asia-Pacific, And Rest Of The World) is expected to grow at a steady cagr forecast till 2030 owing to the growing incidence of pulmonary embolism, venous thromboembolism (vte) and technological advancement with increasing approvals of device from leading countries across the globe.
The global Inferior Vena Cava Filters Market is estimated to grow at a CAGR of 5.67% during the forecast period from 2024 to 2030. The demand for Inferior Vena Cava Filters is primarily being boosted by the growing incidence of pulmonary embolism and venous thromboembolism. Furthermore, the inferior vena cava filter market is anticipated to grow on account of a large number of ongoing improvements in product development, technological advancement, and approvals of device from leading countries contributing to the overall growth of the inferior vena cava market. These are some of the major drivers that are responsible in contributing to the positive growth of the inferior vena cava market during the forecast period from 2024-2030.
Inferior Vena Cava Filters Market Dynamics:
The inferior vena cava filters (IVCF) plays an important role in the prevention of pulmonary embolism and venous thromboembolism. According to the study of Australian Government Department of Health and Aged Care (2021), venous thromboembolism (VTE) poses a significant threat to health. Annually, over 17,000 Australians will have pulmonary embolism every year, and the incidence increases in the aging population.
Furthermore, the study conducted under National Library of Medicines (NIH) 2020, "Pulmonary embolism prevalence among emergency department cohorts: A systematic review and meta-analysis by country of study", stated that the prevalence of pulmonary embolism in Europe was 23% and in North America was 8%. As a result these statistics and data are expected to increase the future use of inferior vena cava filters thus fueling the future market of the Inferior Vena Cava Filters.
Additionally, the increasing approvals of devices from leading industries companies are also playing the major role in boosting the overall future market of inferior vena cava filters. In December 2022, Retrievable Inferior Vena Cava Filter-ZYLOX OctoplusTM received approval from China's National Medical Products Administration (NMPA). This filter, is designed to prevent pulmonary embolism (PE) mainly caused by deep vein thrombosis (DVT) in the peripheral vasculature. Thus, with prominent manufacturers obtaining regulatory clearance for IVCF products, healthcare providers are keen to incorporate these advanced solutions into their treatment protocols. Their focus lies on improving patient outcomes and minimizing the risks associated with venous thromboembolism.
Additionally, In January, 2024 Cook Medical received FDA clearance for its Celect Platinum Vena Cava filter and Gunther Tulip Vena Cava Filter. The Celect Vena Cava Filter stands out for its enhanced flexibility and ease of insertion compared to earlier filter models. Additionally, boasting a retrieval rate exceeding 90%, it offers added assurance in terms of retrieval success. Thus the recent approvals and growing demand of inferior vena cava filters are reflecting the future market growth of inferior vena cava filters.
However, the risk of complication such as movement of IVCF from its original site, filter fracture, filter perforation or the blood clot formation within the filter and issues related with retrieval may hinder the market demand of Inferior Vena Cava Filters.
Inferior Vena Cava Filters Market Segment Analysis:
Inferior Vena Cava Filters Market By Product Type (Retrievable Inferior Vena Cava Filters, Permanent Inferior Vena Cava Filters), Material (Non-Ferromagnetic Material, Ferromagnetic Materials), Application (Treatment Of Venous Thromboembolism, Prevention Of Pulmonary Embolism), End-User (Hospitals, Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest Of The World)
In the product segment of the Inferior Vena Cava Filters market, the Retrievable Inferior Vena Cava Filters category is estimated to mass a significant revenue share in the Inferior Vena Cava Filters Market in 2023. This can be attributed to the various advantages and applications provided by the Retrievable Inferior Vena Cava Filters. Inferior vena cava (IVC) filters are medical devices which helps in preventing blood clots from traveling to the lungs, which can cause a condition known as pulmonary embolism. These filters are typically implanted in the inferior vena cava, the large vein that carries deoxygenated blood from the lower body to the heart. Pulmonary embolism (PE) is a serious medical condition which is characterized by the sudden blockage of one or more arteries in the lungs by blood clots. These clots usually originate in the deep veins of the legs, a condition known as deep vein thrombosis (DVT), and then travel through the bloodstream to the lungs.
These filters can be removed once the risk of pulmonary embolism has passed. They are often used for temporary protection against pulmonary embolism making patients suitable who only require short-term prophylaxis, such as those undergoing high-risk surgeries or trauma. Besides this the Retrievable filters offer flexibility such as if the risk of pulmonary embolism decreases or resolves, the filter can be safely removed. Additionally, removing a retrievable filter once it is no longer needed reduces the risk of long-term complications associated with permanent filter placement. The retrieval procedure for retrievable filters is typically less invasive than the initial placement procedure. It often involves a simple catheter-based technique, performed under fluoroscopic guidance, and can be done on an outpatient basis. Hence all the factors and advancement in technology are promoting the overall market size of Inferior Vena Cava Filter during the forecast period as the patients who require temporary protection against pulmonary embolism, the ability to have the filter removed once the risk has passed can improve overall comfort and quality of life.
North America Is Expected To Dominate The Overall Inferior Vena Cava Market:
North America is expected to account for the highest proportion of the Inferior Vena Cava Filters Market in 2023, out of all regions. This is due to the presence of a large patient pool suffering from incidence of pulmonary embolism and venous thromboembolism. DVT is the most common cause of pulmonary embolism. According to the latest data provided by the American Lung Association (2023), in the United States the annual incidence of pulmonary embolism is around 900,000 every year.
Additionally, as per the latest data provided by the American Lung Association (2023), approximately 33% of individuals who have had a deep vein thrombosis or pulmonary embolism will face a recurrence of pulmonary embolism within a decade. Hence, these statistics and data are expected to increase the future use of inferior vena cava filters thus fuelling the future market of the Inferior Vena Cava Filters in North America.
Additionally, leading companies in the inferior vena cava filter market are prioritizing partnership agreements to expand their distribution networks and improve customer satisfaction. By forging strategic alliances, these companies aim to broaden their market reach and deliver enhanced value to their customer base. For instance, in June 2022, Cordis-X a US- based manufacturer announced the investment in Adient Medical, a US based manufacturer of next generation IVC filter that provide protection against pulmonary embolism. Through this partnership, Cordis aims to expand its product further with solutions that meet unmet needs in cardiovascular health.
Furthermore, in North America individuals undergoing major surgery (e.g., orthopaedic surgery), trauma patients, and those with contraindications to anticoagulant therapy require IVC filters as these filters play a crucial role in the prevention and management of VTE in North America.
Inferior Vena Cava Filters Market Key Players:
Some of the key market players operating in the Inferior Vena Cava Filters include Cook, Radcliffe Medical Media., Teleflex Incorporated, Merit Medical Systems, Inc., Cardinal Health, Inc., Argon Medical Devices, Inc., BD, Medtronic, Abbott Laboratories, Terumo Corporation, Johnson & Johnson Services, Inc., Boston Scientific Corporation, Cordis., C.R. Bard, Inc., Mermaid Medical, LifeTech Scientific Corporation, Argon Medical Devices., Masimo., B. Braun Interventional Systems Inc., Braile Biomdica.
Recent Developmental Activities In The Inferior Vena Cava Filters Market:
Key Takeaways From The Inferior Vena Cava Filters Market Report Study
Target Audience Who Can Be Benefited From This Inferior Vena Cava Filters Market Report Study
Frequently Asked Questions For The Inferior Vena Cava Filters Market:
Inferior vena cava (IVC) filters are medical devices which helps in preventing blood clots from traveling to the lungs, which can cause a condition known as pulmonary embolism. These filters are typically implanted in the inferior vena cava, the large vein that carries deoxygenated blood from the lower body to the heart.
The global Inferior Vena Cava Filters Market is estimated to grow at a CAGR of 5.67% during the forecast period from 2024 to 2030.
The demand for Inferior Vena Cava Filters is primarily being boosted by the growing incidence of pulmonary embolism and venous thromboembolism. Furthermore, the inferior vena cava filter market is anticipated to grow on account of a large number of ongoing improvements in product development, technological advancement, and approvals of device from leading countries contributing to the overall growth of the inferior vena cava market. These are some of the major drivers that are responsible in contributing to the positive growth of the inferior vena cava market during the forecast period from 2024-2030.
Some of the key market players operating in the Inferior Vena Cava Filters include Cook, Radcliffe Medical Media., Teleflex Incorporated, Merit Medical Systems, Inc., Cardinal Health, Inc., Argon Medical Devices, Inc., BD, Medtronic, Abbott Laboratories, Terumo Corporation, Johnson & Johnson Services, Inc., Boston Scientific Corporation, Cordis., C.R. Bard, Inc., Mermaid Medical, LifeTech Scientific Corporation, Argon Medical Devices., Masimo., B. Braun Interventional Systems Inc., Braile Biomdica.
North America is expected to account for the highest proportion of the Inferior Vena Cava Filters Market in 2023, out of all regions. This is due to the presence of a large patient pool suffering from incidence of pulmonary embolism and venous thromboembolism.